IQVIA (IQV) Set to Announce Earnings on Thursday

IQVIA (NYSE:IQV - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect IQVIA to post earnings of $2.19 per share for the quarter. IQVIA has set its FY24 guidance at $10.95-11.25 EPS and its FY 2024 guidance at 10.950-11.250 EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the firm posted $2.54 EPS. The business's revenue was up 3.5% on a year-over-year basis. On average, analysts expect IQVIA to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Down 2.8 %

IQV traded down $6.76 during trading hours on Thursday, hitting $234.08. 1,061,416 shares of the company's stock were exchanged, compared to its average volume of 973,451. The stock has a market cap of $42.49 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 2.31 and a beta of 1.50. IQVIA has a 1-year low of $167.42 and a 1-year high of $261.73. The stock's 50-day moving average is $245.50 and its two-hundred day moving average is $222.69. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. UBS Group lifted their target price on IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. Guggenheim lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. SVB Leerink initiated coverage on IQVIA in a research report on Monday, February 26th. They issued an "outperform" rating and a $290.00 target price on the stock. BTIG Research started coverage on shares of IQVIA in a research note on Tuesday, February 13th. They issued a "buy" rating and a $285.00 price objective on the stock. Finally, Evercore ISI lifted their price target on IQVIA from $255.00 to $265.00 and gave the company a "market outperform" rating in a research note on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $256.80.

Insider Transactions at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the firm's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company's stock, valued at $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 1,000 shares of the company's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock valued at $10,331,003 in the last 90 days. 1.60% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.